Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

Revakinagene taroretcel (NT-501) is an encapsulated cell therapy producing ciliary neurotrophic factor that slowed retinal degeneration in patients with macular telangiectasia type 2 (MacTel) in ph…

Read the full article here

Related Articles